What did @afroditi_kasi actually say?
Honestly? It is nearly impossible to tell. The transcript attributed to this video is incoherent, referencing "East Korean issue," musical ability, and bringing "art to things" in a way that bears no clear relationship to the hashtags about andropause, testosterone, or male hypogonadism. Either the transcript was auto-generated from a non-English audio source and failed badly, or the audio was garbled beyond recovery. What we can say is that the video was tagged under andropause and low testosterone, which tells us something about the intended topic, even if the actual spoken content cannot be evaluated on its merits. We will fact-check the implied subject matter, which is the existence and clinical relevance of andropause and age-related testosterone decline in men, because that is what the creator clearly intended to discuss.
Does the science back up the concept of andropause?
Partially, but the term itself is contested. Unlike female menopause, which involves a relatively abrupt hormonal shift, testosterone decline in men is gradual and highly variable. The science supports that testosterone drops roughly 1-2% per year after age 30, but calling it "male menopause" overstates the parallel.
The Massachusetts Male Aging Study (Feldman et al., 2002, Journal of Clinical Endocrinology and Metabolism) found that total testosterone declined about 1.6% per year in a large population cohort. Bioavailable testosterone fell even faster. But not all men become symptomatic, and many older men maintain levels well within a functional range. The Endocrine Society draws a firm distinction between symptomatic hypogonadism, which has defined diagnostic criteria, and the normal aging trajectory. A diagnosis of hypogonadism requires both low serum testosterone confirmed on at least two morning samples and clinical symptoms. It is not a default condition of midlife. The European Male Aging Study (Wu et al., 2010, New England Journal of Medicine) found that only about 2.1% of men aged 40-79 met strict criteria for late-onset hypogonadism. That is a long way from the cultural narrative that andropause is a universal male experience.
What did the video get wrong or right?
Because the transcript is uninterpretable, we cannot assign credit or fault to specific spoken claims. What we can assess is the framing through hashtags. Using "MaleMenopause" as a descriptor is misleading. It implies a discrete hormonal event analogous to female menopause, which the literature does not support. The American Urological Association and the Endocrine Society both discourage the term because it encourages over-diagnosis and, consequently, over-treatment.
The hashtag "HormoneBalance" is a red flag phrase that has no clinical definition. It is marketing language, not medicine. If the video was promoting TRT as a solution for vague midlife symptoms under the banner of "hormone balance," that would be a significant overstep. TRT carries real risks, including erythrocytosis, suppression of spermatogenesis, and potential cardiovascular effects that remain under active research (Lincoff et al., 2023, New England Journal of Medicine). These are not trivial concerns to skip past in a 307,000-view Instagram video.
What should you actually know about testosterone and aging?
Age-related testosterone decline is real, but the gap between "my levels dropped" and "I need TRT" is wider than social media makes it look. Symptoms attributed to low testosterone, fatigue, reduced libido, mood changes, and body composition shifts, overlap heavily with sleep disorders, metabolic syndrome, depression, and thyroid dysfunction. Treating the wrong thing because a hashtag told you it was andropause is a genuine clinical risk.
If you are concerned about your testosterone levels, the appropriate path is a morning serum total testosterone test, ideally repeated, interpreted by a clinician who will also assess sex hormone-binding globulin, LH, and FSH. Context matters. A level of 350 ng/dL means something very different in a 35-year-old with symptoms than in a 72-year-old who feels fine. The TRAVERSE trial (Lincoff et al., 2023, NEJM) provided the largest randomized data yet on cardiovascular outcomes with TRT, finding non-inferiority to placebo for major cardiac events but a higher rate of pulmonary embolism and atrial fibrillation. That is not a reason to avoid TRT when it is genuinely indicated. It is a reason to have an actual clinical conversation rather than self-diagnosing from Instagram content.